Marine Natural Products, Gut Microbiota and Health Benefits

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 7357

Special Issue Editor


E-Mail Website
Guest Editor
Korea Maritime and Ocean University, Busan 49112, Republic of Korea
Interests: functional food; lipid nutrition; brain function; N-3 polyunsaturated fatty acids; nutraceuticals
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Gut microbiota colonize the body in different regions for different functions, and the study of this is a particularly relevant topic at present. The major physiological functions of gut microbiota include various metabolic activities that ultimately have important effects on the immune system, and also act to protect the colonized host against invasions by transient microbes. Therefore, the gut microbiota is both a target for nutritional intervention and a factor influencing the biological activity of food compounds and additives acquired orally.

Marine natural products can supply a number of beneficial and health-promoting ingredients. In this Special Issue of Marine Drugs, authors are invited to submit recent research papers on novel prospects of marine natural products related to human health and reciprocal interactions between gut microbiota and marine natural products including polysaccharides, carotenoids, polyphenols, polyunsaturated fatty acids, phytosterols and di/sequi-terpenes. We also welcome research related to developing new nutraceuticals and therapeutic agents from natural marine products and from microbiota metabolites.

Dr. Sun Young Lim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine ingredient
  • gut microbiota
  • bowel
  • polysaccharides
  • polyphenols
  • carotenoids
  • prebiotics
  • probiotics
  • seafood

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 5028 KiB  
Article
Fuc-S—A New Ultrasonic Degraded Sulfated α-l-Fucooligosaccharide—Alleviates DSS-Inflicted Colitis through Reshaping Gut Microbiota and Modulating Host–Microbe Tryptophan Metabolism
by Haitao Xiao, Jinxiu Feng, Jiao Peng, Peigen Wu, Yaoyao Chang, Xianqian Li, Jinhui Wu, Haifeng Huang, Huan Deng, Miao Qiu, Yuedong Yang and Bin Du
Mar. Drugs 2023, 21(1), 16; https://doi.org/10.3390/md21010016 - 25 Dec 2022
Cited by 4 | Viewed by 2243
Abstract
Scope: The dysbiosis of intestinal microecology plays an important pathogenic role in the development of inflammatory bowel disease. Methods and Results: A polysaccharide named Fuc-S, with a molecular weight of 156 kDa, was prepared by the ultrasonic degradation of fucoidan. Monosaccharide composition, FTIR, [...] Read more.
Scope: The dysbiosis of intestinal microecology plays an important pathogenic role in the development of inflammatory bowel disease. Methods and Results: A polysaccharide named Fuc-S, with a molecular weight of 156 kDa, was prepared by the ultrasonic degradation of fucoidan. Monosaccharide composition, FTIR, methylation, and NMR spectral analysis indicated that Fuc-S may have a backbone consisting of →3)-α-L-Fucp-(1→, →4)-α-L-Fucp-(1→ and →3, 4)-α-D-Glcp-(1→. Moreover, male C57BL/6 mice were fed three cycles of 1.8% dextran sulfate sodium (DSS) for 5 days and then water for 7 days to induce colitis. The longitudinal microbiome alterations were evaluated using 16S amplicon sequencing. In vivo assays showed that Fuc-S significantly improved clinical manifestations, colon shortening, colon injury, and colonic inflammatory cell infiltration associated with DSS-induced chronic colitis in mice. Further studies revealed that these beneficial effects were associated with the inhibition of Akt, p-38, ERK, and JNK phosphorylation in the colon tissues, regulating the structure and abundance of the gut microbiota, and modulating the host–microbe tryptophan metabolism of the mice with chronic colitis. Conclusion: Our data confirmed the presence of glucose in the backbone of fucoidan and provided useful information that Fuc-S can be applied as an effective functional food and pharmaceutical candidate for IBD treatment. Full article
(This article belongs to the Special Issue Marine Natural Products, Gut Microbiota and Health Benefits)
Show Figures

Figure 1

13 pages, 895 KiB  
Article
Functional Properties of Dunaliella salina and Its Positive Effect on Probiotics
by Ivana Hyrslova, Gabriela Krausova, Iva Mrvikova, Barbora Stankova, Tomas Branyik, Hana Malinska, Martina Huttl, Antonin Kana and Ivo Doskocil
Mar. Drugs 2022, 20(12), 781; https://doi.org/10.3390/md20120781 - 15 Dec 2022
Cited by 8 | Viewed by 2748
Abstract
The unicellular green microalga Dunaliella is a potential source of a wide range of nutritionally important compounds applicable to the food industry. The aim of this study was to assess the effect of Dunaliella salina dried biomass on the growth and adherence of [...] Read more.
The unicellular green microalga Dunaliella is a potential source of a wide range of nutritionally important compounds applicable to the food industry. The aim of this study was to assess the effect of Dunaliella salina dried biomass on the growth and adherence of 10 strains of Lactobacillus, Lacticaseibacillus, and Bifidobacterium. The immunomodulatory, antioxidant, and cytotoxic effects of D. salina on human peripheral mononuclear cells and simulated intestinal epithelial cell lines Caco-2 and HT-29 were evaluated. Furthermore, the hypocholesterolemic effects of the microalgae on lipid metabolism in rats fed a high-fat diet were analyzed. The addition of D. salina biomass had a positive effect on the growth of nine out of 10 probiotics and promoted the adherence of three bifidobacteria strains to human cell lines. The antioxidant and immunomodulatory properties of D. salina were concentration-dependent. The inflammatory cytokines (TNF-α and IL-6) were significantly increased following Dunaliella stimulation at the lowest concentration (0.5% w/v). Eight week supplementation of D. salina to the diet of hypercholesteromic rats significantly decreased the serum concentrations of LDL-C, VLDL, IDL-B, and IDL-C. D. salina is not cytotoxic in intestinal cell models; it promotes adherence of selected bifidobacteria, it affords immunomodulatory and antioxidant effects, and its addition to diets may help decrease atherosclerosis risk factors. Full article
(This article belongs to the Special Issue Marine Natural Products, Gut Microbiota and Health Benefits)
Show Figures

Figure 1

18 pages, 30010 KiB  
Article
The Ameliorative Effect of COST on Diet-Induced Lipid Metabolism Disorders by Regulating Intestinal Microbiota
by Huimin You, Xiaoyi Deng, Yan Bai, Jincan He, Hua Cao, Qishi Che, Jiao Guo and Zhengquan Su
Mar. Drugs 2022, 20(7), 444; https://doi.org/10.3390/md20070444 - 07 Jul 2022
Cited by 5 | Viewed by 1799
Abstract
Background: Chitosan oligosaccharides, with an average molecular weight ≤ 1000 Da (COST), is a natural marine product that has the potential to improve intestinal microflora and resist lipid metabolism disorders. Methods: First, by establishing a mice model of lipid metabolism disorder induced by [...] Read more.
Background: Chitosan oligosaccharides, with an average molecular weight ≤ 1000 Da (COST), is a natural marine product that has the potential to improve intestinal microflora and resist lipid metabolism disorders. Methods: First, by establishing a mice model of lipid metabolism disorder induced by a high fat and high sugar diet, it is proven that COST can reduce lipid metabolism disorder, which may play a role in regulating intestinal microorganisms. Then, the key role of COST in the treatment of intestinal microorganisms is further confirmed through the method of COST-treated feces and fecal bacteria transplantation. Conclusions: intestinal microbiota plays a key role in COST inhibition of lipid metabolism disorder induced by a high fat and high sugar diet. In particular, COST may play a central regulatory role in microbiota, including Bacteroides, Akkermansia, and Desulfovibrio. Taken together, our work suggests that COST may improve the composition of gut microbes, increase the abundance of beneficial bacteria, improve lipid metabolism disorders, and inhibit the development of metabolic disorders. Full article
(This article belongs to the Special Issue Marine Natural Products, Gut Microbiota and Health Benefits)
Show Figures

Figure 1

Back to TopTop